More important, we established a genetically engineered mouse model (GEMM) to conditionally interrupt Klf5 acetylation, providing a unique animal model to address the role of Ac-KLF5 in the progression of PTEN-deficient prostate cancer (24). This evidence concerns the gene KLF5 and Familial prostate cancer.